Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Animal Spirits at OurPet’s Company (OPCO) are Propelling Performance

The management at OurPet’s Company (OTCQX: OPCO) is driven by animal spirits. They’ve taken the quite mundane business of pet care and turned it into a high tech, high touch enterprise. Products now range from the groundbreaking OurPets® Big Dog Feeder® (http://dtn.fm/hG4WS) to the Intelligent Pet Care™ line (http://dtn.fm/dK3Al), which uses digital technologies to enhance […]

Cellceutix Corp. (CTIX) Advances Pipeline toward Multi-billion Dollar Opportunities, Piques Peer Interest along the Way

Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several key markets. Advancements of its current pipeline – spanning dermatology, cancer, infectious disease and gastrointestinal […]

Singlepoint, Inc. (SING) Offers Update on Corporate Initiatives Related to SingleSeed Subsidiary

Before the opening bell, Singlepoint, Inc. (OTC: SING) issued an update on the corporate initiatives being taken by its SingleSeed subsidiary in order to better position itself in the growing domestic cannabis industry. Following November’s vote, more than half of all U.S. states have now legalized marijuana for either recreational or medicinal purposes, leading to […]

Neuralstem, Inc. (CUR) Gets Aegis Update

Neuralstem, Inc. (NASDAQ: CUR) is a biotechnology company whose patented technology allows for the production, on a commercial level, of a number of types of central nervous stem cells. These are in the development stage for the treatment of conditions and diseases of the central nervous system. The company recently announced the start of enrollment […]

Singlepoint (SING) Subsidiary Looks to Help Cannabis Merchants Build Trust, Increase Customer Loyalty

A leading provider of mobile technology and mobile payment solutions serving various markets and industries, Singlepoint, Inc. (OTC: SING) has its eyes set on the fast-growing cannabis industry, aiming to help legal marijuana businesses build trust and increase customer loyalty via subsidiary SingleSeed and its highly reliable payment processing and marketing tools. With eight more […]

European Patent Dispute Spurs Buying Opportunity with Higher Price Target for Alder Biopharmaceuticals (ALDR)

A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), according to an analysis report (http://dtn.fm/9UkRd) released by Aegis Capital Corp on November 23. As such, Aegis analysts reiterated a ‘Buy’ rating […]

Singlepoint, Inc. (SING) CEO Discusses Influx of Calls from Cannabis Dispensaries on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for […]

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two […]

 

From Our Blog

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Steps into Spotlight as China Tightens Rare Earth Controls

November 7, 2025

This article has been disseminated on behalf of  Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising. A tectonic shift in the global minerals landscape has crystallized: China’s Ministry of Commerce announced this month that it is expanding export controls over key rare-earth elements and related processing equipment, marking a strategic tightening […]

Rotate your device 90° to view site.